The trial confirms expected bleeding harm, but the field may be asking the wrong question entirely
X post ↗View all ESC 2026 trials
Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial
Konstantinos D. RizasKonstantinos MourouzisDominik RathChristoph B. OlivierLaura Elisa Villegas SierraTheofanis KorovesisAmin PolzinAmani Al TawilReza WakiliLukas von StülpnagelKatharina MayerMarion JanischTanja UlrichSarah LangS. K. G. MaierFlorian BrattingerLorenz Bott‐FlügelHarilaos BogossianKonstantinos IliodromitisLuisa FreyerJulius SteffenKonstantin StarkElodie EiffenerLauren E. SamsTobias PetzoldAxel LinkeFelix M. HeidrichSamuel SossallaSaif ZakoNikolaos DagkonakisAndreas SchäferFrank EdelmannDavid M. LeistnerMariya MaslarskaFabian KnebelGeorg NickenigBlerim LuaniTienush RassafHüseyin InceIbrahim AkinMicha T. MaederMeinrad GawazHans-Josef FeistritzerNorbert FreyStefan KääbRiza SahinMatthias PauschingerThomas StiermaierIngo EitelMarc KollumJan Sebastian WolterMichael SchreinlechnerAxel BauerChristoph StellbrinkUlf LandmesserPaulus KirchhofDirk SibbingHölger ThieleAdnan KastratiUlrich MansmannSteffen Maßberg
What happened
DOAC plus potent P2Y12 increases bleeding without reducing ischemic events versus DOAC, clopidogrel, and aspirin.
- WLR 1.19
- 95% CI 0.61-2.32
- P=0.610
- n=602
Does this change practice?
Where experts agree
Multiple experts agree that the findings do not support routine use of potent P2Y12 inhibitors with direct oral anticoagulants in patients with atrial fibrillation and acute coronary syndrome, and that clopidogrel should remain the standard antiplatelet in this setting.
What this trial adds
Experts see EPIDAURUS as confirming that potent P2Y12 inhibitors should not replace clopidogrel alongside a direct oral anticoagulant in patients with atrial fibrillation and acute coronary syndrome, with the trial stopped early for excess bleeding and no ischemic benefit.
Published field read
The expert reaction is one-sided: no one defends the experimental strategy, and the early stop for harm cements the view that potent P2Y12 inhibitors paired with an anticoagulant carry unacceptable bleeding risk in this population. Several clinicians stress that clopidogrel remains the appropriate antiplatelet choice. The live question is whether future trials should instead test temporarily pausing the anticoagulant around the acute event rather than escalating antiplatelet potency.
Still open
Questions raised in published commentaryDavide Capodanno raises whether the field is asking the wrong question entirely, noting that the next approach being tested is temporarily stopping the oral anticoagulant during the acute phase rather than intensifying antiplatelet therapy.
It remains to be seen whether guidelines will formally update their recommendations on the basis of this early-stopped trial, and whether any subgroup might still benefit from short-term potent P2Y12 inhibition.
Context from published commentary. Source summaries are not a new guideline recommendation.
Who says what
Christopher Granger
Practice takeCardiologist, Duke Clinical Research InstituteClopidogrel remains the appropriate P2Y12 inhibitor for the majority of these patients
Original post ↗
C. Michael GibsonResults readoutInterventional / Structural Cardiology · Beth Israel Deaconess Medical Center
Dual antithrombotic therapy with intensified P2Y12 inhibition raised bleeding without reducing ischemic events
X post ↗Show 5 more perspectivesShow fewer perspectives
Konstantinos Rizas
Results readoutInterventional cardiologist, Ludwig Maximilians University MunichFirst trial of its kind answers the question: potent P2Y12 inhibitors with anticoagulants are not supported
Original post ↗
Edgardo AlaniaResults readout
Highlights the BARC 3 or greater bleeding signal (HR 3.54) and concludes potent P2Y12 inhibition should not routinely replace clopidogrel in this setting.
X post ↗
Gunnar H. HeinePractice take
Warns against combining DOACs and potent P2Y12 inhibitors even for a limited period and notes that temporarily stopping the DOAC is being tested next.
X post ↗Mohammed Al-Qadami
Results readoutSummarizes the key finding that potent P2Y12 inhibition plus a DOAC increased bleeding without ischemic benefit.
X post ↗Sophia Proneikos
@pergament_f“There is something extraordinary in the fact that one of the most perfect theatres of antiquity was built not in the centre of a great city, but in a sanctuary of healing. At the end of the 4th century BCE, among the hills of Argolis, in the Sanctuary of Asclepius at Epidaurus,”
X ↗What should the author answer first?
Upvote a question you would like answered, or open it to join the discussion.
Full evidence
Why the trial, key points, tables, limitations, PICO, abstract, media & sources
Full evidence
Why the trial, key points, tables, limitations, PICO, abstract, media & sources
View Full Paper
Ask AI
Bookmark
Share
Why the trial?
Patients with atrial fibrillation undergoing PCI for acute coronary syndrome need anticoagulation plus antiplatelet therapy, a combination that trades ischaemic protection against serious bleeding. The optimal early regimen — including escalated single platelet inhibition for one month alongside a NOAC — remained undefined.
Does a 1-month regimen of DOAC plus a potent P2Y12 inhibitor (prasugrel or ticagrelor) reduce ischemic events compared to DOAC plus clopidogrel and in-hospital aspirin in patients with atrial fibrillation and acute coronary syndrome?
Key Points
- To evaluate the efficacy and safety of a 1-month dual antithrombotic therapy combining a direct oral anticoagulant (DOAC) with a potent P2Y12 inhibitor versus a DOAC plus clopidogrel and in-hospital aspirin in patients with atrial fibrillation and acute coronary syndrome.
- Open-label, randomized controlled trial (EPIDAURUS; NCT04981041) conducted across 37 medical centers in Germany and Austria comparing a DOAC plus potent P2Y12 inhibitors (N=302) versus a DOAC plus clopidogrel and in-hospital aspirin (N=300).
- Evaluated primary efficacy endpoints (recurrent ischemic events) and safety endpoints (death and major bleeding) at 6 weeks post-randomization using separate win–loss ratio (WLR) analyses.
- The trial was terminated prematurely after enrolling 602 of an expected 1,474 patients due to safety concerns, revealing higher bleeding rates (BARC type ≥2 and ≥3) with potent P2Y12 inhibitors without a clear reduction in ischemic complications.
- In an exploratory as-treated analysis, the safety WLR demonstrated significantly higher safety complications in the potent P2Y12 inhibitor group (WLR = 0.59, 95% CI: 0.35–0.99, P = 0.047).
- Experiencing a BARC bleeding event ≥2 was associated with a statistically significant increase in subsequent ischemic complications across treatment groups (HR 2.18, 95% CI: 1.16–4.11, P = 0.016).
Evidence details
What drove the result?
| Outcome | Potent P2Y12 | Clopidogrel |
|---|---|---|
| Hierarchical composite: death, stent thrombosis, MI, ischemic stroke, systemic embolism, urgent revascularization | ||
| Win-loss ratio 1.19 (95% CI 0.61-2.32; p=0.610) · no clear ischemic benefit; per-arm counts not reported |
Limitations & tradeoffs
Safety
BARC type >=2 and >=3 bleeding were higher with the potent P2Y12 inhibitor (secondary endpoints; per-arm counts not reported).
Statistical certainty
premature termination (stopped by the DSMB for safety) at 602 of 1,474 planned patients leaves the trial underpowered.
Subgroup caution
the hierarchical win-loss design makes all subsequent analyses, including bleeding, exploratory.
Representation
only 18% of screened patients met inclusion criteria and agreed to participate.
Design limitations
the statistical design was modified during the course of the trial.
Structured PICO
Does a 1-month regimen of DOAC plus a potent P2Y12 inhibitor (prasugrel or ticagrelor) reduce ischemic events compared to DOAC plus clopidogrel and in-hospital aspirin in patients with atrial fibrillation and acute coronary syndrome?
P
Population
602 patients (median age 78, 25.6% female) with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention, followed for 6 months.
I
Intervention
1-month regimen of direct oral anticoagulant (DOAC) plus a potent P2Y12 inhibitor (prasugrel or ticagrelor), followed by transition to clopidogrel between days 27 and 33.
C
Comparator
DOAC plus clopidogrel and in-hospital aspirin (standard in-hospital triple antithrombotic therapy followed by dual antithrombotic therapy with direct factor Xa inhibitors plus clopidogrel).
O
Outcome
Efficacy: hierarchic composite of death, stent thrombosis, myocardial infarction, ischemic stroke, systemic thromboembolism and urgent revascularization evaluated 6 weeks after randomization using win-loss ratio. Safety: hierarchic composite of death and Bleeding Academic Research Consortium (BARC) 3c, 3b, 3a and 2 bleeding evaluated 6 weeks after randomization.composite
Main Result
Effect estimate: WLR 1.19 (95% CI 0.61-2.32)
p-value: p=0.610
In patients with atrial fibrillation and acute coronary syndrome, a 1-month strategy of DOAC plus a potent P2Y12 inhibitor (prasugrel or ticagrelor) increases bleeding without reducing ischemic events compared to clopidogrel.
Limitations
- Prematurely terminated after enrollment of 602 of 1,474 patients due to safety concerns.
- Hierarchical win-loss ratio approach means subsequent analyses are exploratory.
- Standalone bleeding complications were secondary endpoints.
- Selection of escalated P2Y12 inhibitor and factor Xa inhibitor was at the discretion of the treating physician.
- All patients underwent peri-interventional loading with aspirin.
- Only 18% of screened patients met the inclusion criteria and agreed to participate.
- Statistical design was modified during the course of the trial.
- Early termination
- Low event numbers
- Underrepresentation of women, patients younger than 65 years, and STEMI patients
- Population not specifically enriched for high ischemic risk
- Intravascular imaging not systematically collected
Discussion
No takes yet. Share an insight, caveat, or question.
Expert reaction
What experts said about EPIDAURUS
Nature Medicine · ESC Congress 2026
Expert labels are toward EPIDAURUS's result, from named public quotes (n=2). As of Aug 30, 2026.
Where experts stand
Experts see EPIDAURUS as confirming that potent P2Y12 inhibitors should not replace clopidogrel alongside a direct oral anticoagulant in patients with atrial fibrillation and acute coronary syndrome, with the trial stopped early for excess bleeding and no ischemic benefit.
The expert reaction is one-sided: no one defends the experimental strategy, and the early stop for harm cements the view that potent P2Y12 inhibitors paired with an anticoagulant carry unacceptable bleeding risk in this population. Several clinicians stress that clopidogrel remains the appropriate antiplatelet choice. The live question is whether future trials should instead test temporarily pausing the anticoagulant around the acute event rather than escalating antiplatelet potency.
Agreement
Multiple experts agree that the findings do not support routine use of potent P2Y12 inhibitors with direct oral anticoagulants in patients with atrial fibrillation and acute coronary syndrome, and that clopidogrel should remain the standard antiplatelet in this setting.
4 clinicians say this directly
2 takes classified by contention axis so far — the map appears as more land.
Still unclear
Davide Capodanno raises whether the field is asking the wrong question entirely, noting that the next approach being tested is temporarily stopping the oral anticoagulant during the acute phase rather than intensifying antiplatelet therapy. It remains to be seen whether guidelines will formally update their recommendations on the basis of this early-stopped trial, and whether any subgroup might still benefit from short-term potent P2Y12 inhibition.
Key expert perspectives
SPSophia Proneikos
“There is something extraordinary in the fact that one of the most perfect theatres of antiquity was built not in the centre of a great city, but in a sanctuary of healing. At the end of the 4th century BCE, among the hills of Argolis, in the Sanctuary of Asclepius at Epidaurus,”
The trial confirms expected bleeding harm, but the field may be asking the wrong question entirely
Capodanno notes that the safety stop for excess bleeding with ticagrelor or prasugrel is unsurprising, given what is already known. He challenges whether intensifying antiplatelet therapy was the right approach and points to upcoming trials that instead test temporarily stopping the oral anticoagulant during the acute coronary event.
Distilled from their postX post
CGChristopher GrangerCardiologist, Duke Clinical Research InstitutePractice takeAug 30
Clopidogrel remains the appropriate P2Y12 inhibitor for the majority of these patients
Granger reinforces that clopidogrel should remain the standard antiplatelet agent in this population, a position consistent with current practice that EPIDAURUS now supports with randomized evidence.
Distilled from their postOriginal post
Implication
Avoid potent P2Y12 inhibitors with DOAC after PCI in AF; challenges assumptions favoring early intensified antiplatelet therapy.
Abstract
The selection of the optimal antithrombotic regimen in patients with atrial fibrillation and acute coronary syndrome remains challenging. Previous trials have demonstrated that dual antithrombotic therapy (DAT), consisting of direct oral anticoagulants (DOACs) plus a P2Y12 inhibitor, reduces bleeding compared to a triple-therapy regimen using vitamin K antagonists. However, subsequent meta-analyses have suggested an increased risk of ischemic events with DAT, particularly within the first month of treatment. Clopidogrel has been the predominant P2Y12 inhibitor used across these studies, despite the risk of high on-treatment platelet reactivity when using this drug. In this study, we conducted an open-label, randomized controlled trial (EPIDAURUS) in patients with atrial fibrillation and acute coronary syndrome, designed to assess the efficacy and safety of a 1-month regimen of DOAC plus potent P2Y12 inhibitor (prasugrel or ticagrelor) compared to DOAC plus clopidogrel and in-hospital aspirin. The primary outcomes of the trial were an efficacy endpoint, recurrent ischemic events and safety endpoints, including death and major bleeding, which were evaluated 6 weeks after randomization using separate win−loss ratio analyses. The study was prematurely terminated after enrollment of 602 patients (154 female) of an expected 1,474 patients, owing to safety concerns raised by the Data and Safety Monitoring Board. Exploratory analyses of secondary safety endpoints, including bleeding type ≥2 and ≥3 according to the Bleeding Academic Research Consortium scale, revealed that, compared to clopidogrel and in-hospital aspirin, treatment with a potent P2Y12 inhibitor was associated with higher bleeding rates without a clear reduction in the risk of ischemic complications. These findings do not support the routine use of potent P2Y12 inhibitors in combination with DOACs in this patient population. ClinicalTrials.gov identifier: NCT04981041 .
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Cite This Study
Rizas et al. (2026) conducted an RCT in Atrial fibrillation and acute coronary syndrome (n=602). DOAC plus potent P2Y12 inhibitor (prasugrel or ticagrelor) vs. DOAC plus clopidogrel and in-hospital aspirin was evaluated on Hierarchic composite of death, stent thrombosis, myocardial infarction, ischemic stroke, systemic thromboembolism and urgent revascularization (WLR 1.19, 95% CI 0.61-2.32, p=0.610). In patients with atrial fibrillation and acute coronary syndrome, a 1-month regimen of a DOAC plus a potent P2Y12 inhibitor did not reduce ischemic events (WLR 1.19) but increased bleeding.